This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HMGA1 / High mobility group protein HMG-I/HMG-Y · IHC design guide
Design Immunohistochemistry for HMGA1
Plan chromogenic HMGA1 IHC in paraffin sections with a catalog antibody validated at 1:50–1:200 (datasheet M01043). Use the nuclear tissue pattern and cell-specific staining examples to choose controls and interpret results (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
HMGA1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining across tissues (HPA tissue IHC) | |
| Staining pattern | Nuclear signal across tissues, varying by cell type (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M01043) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Normal cells can also show nuclear staining (HPA tissue IHC) | |
| Regulation | Esophagus has tissue-enhanced RNA (HPA RNA specificity) | |
| Isoform / epitope | 3 isoforms (HMG-I/Y/R); epitope coverage unknown (UniProt) |
Section 1
Recommended HMGA1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet: M01043) with published HMGA1 staining methods for pancreatic, urothelial, and breast cancer specimens (PMC3092591; PMC12984743; PMC5661362).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M01043) |
| Fixation | Image fixative and duration unreported (datasheet M01043); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M01043); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M01043) |
| Primary antibody | Rabbit monoclonal (clone 18H23) anti-HMGA1, 1:50-1:200 (datasheet M01043) |
| Primary incubation | Overnight at 4 °C (datasheet M01043) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M01043) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | HMGA1-positive staining in endocrine cells of appendix (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in all tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet: M01043); the published alternatives use citrate retrieval (PMC12984743; PMC5661362).
Section 2
What Is the Expected HMGA1 Staining Pattern?
HMGA1 is a nuclear and chromosome-associated protein without a transmembrane segment (UniProt P17096). In paraffin-section IHC, expect nuclear staining across tissues, with cell-dependent intensity (HPA tissue IHC: nuclear expression in all tissues; Enhanced reliability). High staining is documented in breast glandular cells, bronchial respiratory epithelial cells, and several endocrine cell populations (HPA tissue IHC). Interpret each cell population against its own reference pattern.
| Clear nuclear staining in breast glandular or bronchial respiratory epithelial cells, with little staining outside nuclei. | This fits the expected compartment (UniProt P17096: nucleus, chromosome) and documented High staining in those cell types (HPA tissue IHC). Nuclear staining in other tissues can also be expected; the HPA profile reports nuclear expression across tissues, while intensity varies by cell population (HPA tissue IHC). |
| Predominantly cytoplasmic or surface staining, with little nuclear signal, on a chromogenic IHC slide. | This is discordant with the dominant IHC pattern (HPA tissue IHC: nuclear expression). Review morphology and staining controls before calling it HMGA1. Cytosolic localisation is reported as an additional ICC-IF finding, so isolated cytosolic fluorescence should be judged in its own application context (HPA subcellular ICC-IF). |
| Strong staining in adipocytes or ovarian follicle cells, especially without convincing nuclear staining in adjacent cells. | Those cell populations are reported as Not detected by HPA tissue IHC. Investigate cross-reactivity or endogenous detection activity (standard IHC practice). The finding alone does not establish either cause; compare the stained slide with a reagent-omission control and an expected-positive cell population. |
| Diffuse brown colour across nuclei, cytoplasm, and tissue spaces, with little separation between cell populations. | A poorly resolved pattern cannot reliably establish nuclear HMGA1 localisation (UniProt P17096: nucleus; HPA tissue IHC: nuclear expression). Check the detection background and primary-antibody dilution using standard IHC controls (standard IHC practice), then assess whether nuclei remain distinguishable from surrounding tissue. |
| No nuclear signal in a breast glandular or bronchial respiratory epithelial population that is identifiable on the section. | This conflicts with the reported High staining for those populations (HPA tissue IHC). First check section quality, control tissue, retrieval, antibody incubation, and detection steps (standard IHC practice). A single negative slide does not show that the tissue lacks HMGA1. |
💡Expected HMGA1 appearanceCall positive when the relevant cells show convincing nuclear staining, including High signal in documented breast glandular or bronchial epithelial populations (HPA tissue IHC); diffuse staining without nuclear enrichment is suspect (HPA tissue IHC: nuclear expression).
| Nuclear target and absence of a transmembrane segment | Score staining against nuclei and tissue morphology (UniProt P17096: nucleus, chromosome; no transmembrane segment). A membrane-only chromogenic pattern does not match the reported IHC distribution (HPA tissue IHC: nuclear expression). |
| Cell-specific reference intensity | Use the matching cell population as the comparator: endocrine cells in appendix, colon, and duodenum are High; smooth muscle cells are low; adipocytes and ovarian follicle cells are Not detected (HPA tissue IHC). |
| Antibody validation and limits | HPA lists IHC as Enhanced for HPA065612 and HPA068442, both rabbit polyclonals (HPA antibodies). This supports the reported pattern; it does not validate an unlisted catalog antibody or predict its staining at a particular dilution. |
| IF/ICC pattern? | In the separate IF/ICC application, HPA reports supported nucleoplasm and nuclear membrane localisation, plus approved additional cytosolic localisation (HPA subcellular ICC-IF). Treat that as an IF/ICC interpretation reference, not an IHC-P protocol or a reason to score cytoplasm-only IHC as expected. |
| Isoforms, modifications, and retrieval | UniProt lists 3 isoforms and multiple modified residues (UniProt P17096). Their effects on a given antibody's epitope or retrieval response are unspecified here; select retrieval conditions from the antibody's IHC-P instructions and assess them with controls (standard IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected-positive nuclei are blank throughout the slide. | The slide may have failed at retrieval, primary incubation, or detection (standard IHC practice); this result conflicts with High reference staining in selected cell populations (HPA tissue IHC). | Confirm the expected-positive population is present, inspect the run control, then check each IHC-P step against the antibody instructions. Do not assign a target-specific fixation or retrieval sensitivity from the supplied evidence. |
| Nuclei stain weakly, while the tissue and detection controls appear usable. | Antibody concentration, incubation, or retrieval may yield insufficient contrast (standard IHC practice); the supplied HPA and UniProt records do not establish which variable is responsible. | Adjust one parameter at a time within the antibody's IHC-P guidance and compare nuclear contrast in the same reference cell population (standard IHC practice; HPA tissue IHC: cell-specific levels). |
| Brown signal coats tissue edges or fills spaces between cells. | Diffuse deposition or detection background can obscure localisation (standard IHC practice). This distribution cannot be read as the reported nuclear IHC pattern (HPA tissue IHC). | Review washing, blocking, and detection conditions; compare a reagent-omission control, then rescore only well-preserved cells whose nuclei can be identified (standard IHC practice). |
| Adipocytes or ovarian follicle cells stain strongly. | Cross-reactivity or endogenous detection activity is possible (standard IHC practice), because HPA reports these cells as Not detected (HPA tissue IHC). | Check a primary-antibody omission control and the location of signal within cells; compare with expected-positive nuclei on the same run before attributing the signal to HMGA1 (standard IHC practice; HPA tissue IHC). |
| Smooth muscle appears much fainter than nearby stained cells. | Low staining in smooth muscle cells is part of the reported tissue pattern (HPA tissue IHC); intensity differences alone do not establish an assay failure. | Judge nuclear localisation and the run control before changing conditions. Use a documented High cell population, such as bronchial respiratory epithelium, to assess assay performance (HPA tissue IHC; standard IHC practice). |
| IF/ICC shows some cytosolic fluorescence alongside nuclear signal. | HPA reports cytosol as an additional ICC-IF location, while nucleoplasm and nuclear membrane are the supported main locations (HPA subcellular ICC-IF). | Evaluate the fluorescence in the separate IF/ICC guide against its controls. For this chromogenic IHC-P guide, base the expected call on nuclear tissue staining (HPA tissue IHC). |
Experiment evidence
IHC & IF images showing HMGA1 staining
M01043 · IHCIHC analysis of HMGA1 using anti-HMGA1 antibody (M01043). HMGA1 was detected in a paraffin-embedded section of human breast cancer tissue. H
A01043-2 · IFFluorescent image of A549 cell stained with HMGA1 Antibody (C-term).A549 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000137309-HMGA1/tissue/cerebral+cortex#imid_20773256
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000137309-HMGA1/tissue/colon#imid_20773182
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000137309-HMGA1/tissue/liver#imid_20773183
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000137309-HMGA1/tissue/kidney#imid_20773176
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA065612; green = HMGA1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA065612; green = HMGA1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for HMGA1 IHC & IF
🧪Run breast first: glandular cells should show HMGA1 staining (HPA: High in breast glandular cells). Use adipose tissue as the negative tissue, assessing adipocytes for absent signal (HPA: Not detected in adipocytes); on the breast slide, treat cells without specific nuclear staining as internal background references, without assuming a particular non-glandular cell type is HMGA1-negative.
Positive control tissue: Appendix (Endocrine cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HMGA1 in A-431, PODO/TERT256, U2OS, with annotated localisation: Nucleoplasm (supported), Nuclear membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, a concentration-matched rabbit immunoglobulin isotype control, and a biological negative such as HMGA1 knockout material or a validated peptide-block control (caption: rabbit anti-HMGA1 antibody; standard IHC controls). Quench endogenous peroxidase and check for residual DAB background in breast tissue (caption: peroxidase detection with DAB; standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected M01043 caption does not state the fixative (caption: fixative not stated). The reported paraffin-section procedure uses heat-mediated EDTA retrieval at pH 8.0, but whether retrieval is essential has not been established here (caption: heat-mediated EDTA retrieval). Neither a frozen-section nor an IF/ICC ease advantage is established by the supplied evidence; in breast sections, assess peroxidase-related DAB background before scoring nuclear signal (caption: breast tissue, peroxidase detection with DAB; UniProt P17096: nucleus).
HPA tissue IHC evidence for HMGA1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Endocrine cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Granular cells - nucleus | High | Protein (IHC) | HPA → |
Section 3
Advanced HMGA1 IHC Tips
These troubleshooting questions focus on chromogenic HMGA1 IHC in paraffin sections, with one entry on IF/ICC (selected product caption: paraffin section; HPA: nuclear expression).
How should I retrieve HMGA1 when nuclear DAB staining is weak?
Start with heat mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet M01043). The selected product image used this retrieval before staining human breast cancer tissue, but its caption does not report the fixative (selected product caption M01043). If nuclei remain weak, compare retrieval times on matched sections while holding the catalog antibody at its documented 1:50 dilution and overnight 4°C incubation (datasheet M01043; standard IHC practice). Check tissue integrity and include a positive section with expected nuclear staining, since HMGA1 is predominantly nuclear and chromosomal (UniProt P17096: localisation; HPA tissue IHC: nuclear expression).
Does fixation explain inconsistent HMGA1 staining across paraffin sections?
Target specific fixation sensitivity is unknown from the supplied evidence; the selected paraffin tissue caption does not state a fixative (selected product caption M01043). Record the fixative, fixation duration, tissue thickness, and processing history for each block, then compare sections processed under matched conditions (standard IHC practice). If weak staining tracks with one processing batch, repeat the documented EDTA pH 8.0 retrieval on a matched section and inspect morphology before changing antibody concentration (datasheet M01043; standard IHC practice). Use a known staining control in the same run to distinguish a processing problem from a detection problem (standard IHC practice).
Where should convincing HMGA1 chromogenic staining appear?
Prioritize staining within morphologically intact nuclei: HMGA1 is annotated in the nucleus and on chromosomes, and tissue IHC reports nuclear expression across tissues (UniProt P17096: localisation; HPA tissue IHC: profile). Nuclear membrane and nucleoplasmic locations are supported in subcellular images, with cytosol listed as an additional location (HPA subcellular: main and additional locations). Chromogenic sections may not resolve those nuclear subregions reliably, so score nuclear signal consistently against the hematoxylin counterstain (standard IHC practice). Treat isolated diffuse cytoplasmic DAB as inconclusive until controls and tissue morphology support it, especially when nuclei lack signal (HPA tissue IHC: nuclear expression; standard IHC practice).
Can this IHC antibody distinguish HMG-I, HMG-Y, and HMG-R?
The record lists 3 HMGA1 isoforms, HMG-I, HMG-Y, and HMG-R, but the supplied product caption gives no epitope map (UniProt P17096: isoforms; selected product caption M01043). Therefore, a shared nuclear DAB signal cannot establish which isoform contributed without isoform specific validation (UniProt P17096: isoforms; standard IHC interpretation). HMGA1 has annotated modifications including acetylation, ADP ribosylation, and phosphorylation, so epitope accessibility could depend on antibody recognition; no effect is demonstrated here (UniProt P17096: modified residues). For an isoform claim, seek mapped epitope information and an independent isoform selective control before assigning staining to one variant (standard IHC practice).
How can I check HMGA1 localisation with multiplex IF?
Pair the HMGA1 signal with a validated marker for the expected cell type, such as a glandular cell marker in breast tissue, and include a nuclear counterstain (HPA tissue IHC: high in breast glandular cells; standard IF practice). Choose a spectrally separated fluorophore after inspecting tissue autofluorescence; a far red channel can help when shorter wavelength background is high (standard IF practice). Because HMGA1 is nuclear and has no transmembrane segment, permeabilise fixed cells sufficiently for nuclear antibody access while preserving nuclear morphology (UniProt P17096: localisation and topology; standard IF practice). Optimize IF fixation and permeabilisation on IF specimens; the selected paraffin IHC caption supplies no IF fixation conditions (selected product caption M01043).
What causes widespread brown signal despite weak nuclear contrast?
Inspect a no primary control for endogenous peroxidase, nonspecific secondary binding, and pigment before attributing diffuse brown deposits to HMGA1 (standard chromogenic IHC practice). The selected product image used 10% goat serum blocking, a peroxidase conjugated secondary, and DAB; these are documented workflow details for that section (selected product caption M01043). Apply an appropriate peroxidase block and compare matched sections with and without primary antibody, keeping DAB development time consistent (standard chromogenic IHC practice). Recheck whether staining concentrates in intact nuclei, since tissue IHC reports nuclear HMGA1 expression (HPA tissue IHC: profile).
How should I quantify HMGA1 staining across heterogeneous sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and nuclear positivity threshold before scoring, using the same exposure and DAB development conditions across batches (standard chromogenic IHC practice). Report the percentage of positive nuclei and, when intensity is reproducible, an H-score derived from the fractions at each nuclear intensity level (standard IHC scoring practice). Normalize positive nuclei to all evaluable nuclei of the designated cell type, or report positive cell density per mm² of viable tissue (standard IHC quantification practice). Keep glandular and other compartments separate where relevant, because breast glandular cells have high reported staining and HMGA1 expression varies by cell type (HPA tissue IHC: breast glandular cells and cell profile).
When is apparent HMGA1 positivity likely to be an artefact?
Favor signal within intact nuclei of the scored cell population, consistent with HMGA1 nuclear and chromosomal localisation and the tissue IHC profile (UniProt P17096: localisation; HPA tissue IHC: profile). Check cell identity before calling a section negative: adipocytes and ovarian follicle cells were reported as not detected, while breast glandular cells were high (HPA tissue IHC: cell profile). Exclude section edges, folds, and necrotic areas from scoring when staining follows damaged tissue rather than viable nuclei (standard IHC interpretation). Use a no primary control to identify endogenous enzyme signal or nonspecific detection, especially if brown deposits remain outside nuclei (standard chromogenic IHC practice).
Boster reagents
Best HMGA1 / High mobility group protein HMG-I/HMG-Y IHC Antibodies
The catalog includes HMGA1 antibodies with IHC data from human breast cancer paraffin sections and IF data from human A549 cells; one antibody also lists mouse and rat reactivity (catalog; image captions).
Real IHC data
Anti-HMGA1 Rabbit Monoclonal Antibody
Cat # M01043
Real IF data
Anti-HMGA1 Antibody (C-term)
Cat # A01043-2
M01043 lists IHC and ICC/IF applications, with an IHC image from a human breast cancer paraffin section (catalog; M01043 image caption). A01043-2 lists IF and shows nuclear staining in human A549 cells (catalog; A01043-2 image caption).
Which to pick: Choose M01043 for paraffin-section IHC: it is monoclonal, lists IHC at 1:50–1:200, and its IHC caption documents EDTA retrieval at pH 8.0; the fixative is unreported (catalog; M01043 image caption). Choose A01043-2 for IF in human cells based on its A549 image; for ICC specifically, M01043 lists ICC/IF while A01043-2 lists IF only (catalog; A01043-2 image caption). For mouse or rat samples, M01043 is the option with listed reactivity, although its supplied IHC image shows human tissue (catalog; M01043 image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P17096 (HMGA1_HUMAN, High mobility group protein HMG-I/HMG-Y).
- Human Protein Atlas. HMGA1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. HMGA1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm and nuclear membrane. In addition localized to the cytosol..
- Human Protein Atlas. HMGA1 antibody validation summary (2 antibodies).
- HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 — PMC3092591.
- Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma. International journal of molecular sciences 2026 — PMC12984743.
- HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia (New York, N.Y.) 2016 — PMC5110473.
- Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer. Oncology letters 2017 — PMC5661362.
- PubMed PMID:2505228 — UniProt-cited evidence.
- PubMed PMID:2701943 — UniProt-cited evidence.
- PubMed PMID:8414980 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for HMGA1 (High mobility group protein HMG-I/HMG-Y). Expected localisation Nuclear staining across tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M01043). Validated IHC antibody: M01043 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Endocrine cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M01043); 2. Fixation: Image fixative and duration unreported (datasheet M01043); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M01043); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M01043); 8. Primary antibody: Rabbit monoclonal (clone 18H23) anti-HMGA1, 1:50-1:200 (datasheet M01043); 9. Primary incubation: Overnight at 4 °C (datasheet M01043). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Normal cells can also show nuclear staining (HPA tissue IHC); Isoform / epitope: 3 isoforms (HMG-I/Y/R); epitope coverage unknown (UniProt); Regulation: Esophagus has tissue-enhanced RNA (HPA RNA specificity). Evidence: UniProt P17096, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm and nuclear membrane. In…, Datasheet M01043, PMC3092591, PMC12984743. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/HMGA1/immunohistochemistry-ihc-guide.